Sarcoma Clinical Trials
Patients with sarcoma can consider clinical trials to expand their range of treatment options. In a clinical trial, researchers provide one group of patients with an investigational therapy, such as a novel chemotherapy drug, while providing a second group of patients with the best treatment that is currently available. This helps patients access the newest treatments before they are offered to the public, while helping researchers determine which treatments produce the best outcomes and the fewest side effects.
The Only Florida-based NCI-designated Comprehensive Cancer Center
Recognized for its scientific excellence, Moffitt is the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida.
Recent sarcoma clinical trials have investigated treatments such as:
- New medications for chemotherapy-resistant sarcomas
- New drug combinations for sarcomas that cannot be surgically removed
- Proton therapy as an alternative to X-ray-based radiation therapy
- Peripheral stem cell transplantation as a potential sarcoma treatment
- Antibody-based treatments for recurrent sarcomas
- Less toxic treatments for pediatric sarcoma patients
Other sarcoma clinical trials have explored risk factors, screening methods, preventive options and techniques to improve the likelihood of early diagnosis. For instance, researchers have linked several genetic syndromes to an increased risk of developing sarcoma, and this information has led to better awareness for these individuals. Through clinical trials, researchers are improving options not just for current patients, but for every individual who will face a sarcoma diagnosis in the future.
As part of our commitment to ongoing research, Moffitt Cancer Center offers an extensive range of clinical trials, with options for patients with many different types and stages of sarcoma. These trials are overseen by our expert oncologists and research professionals; careful monitoring ensures that every participant receives the best possible treatment for his or her needs. In recognition of our extensive research efforts, the National Cancer Institute awarded Moffitt Cancer Center with its prestigious Comprehensive Cancer Center designation.
For more information about sarcoma clinical trials, or to enroll in one of Moffitt Cancer Center’s ongoing trials, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Referrals are not required to seek treatment at Moffitt and participate in our clinical trials.
Helpful Links:
-
Clinical Trials
CLINICAL TRIAL 23281
Metastatic Ewing s Trial Testing Schedule Enhancement to Improve Outcomes
Condition: Sarcoma
Intervention: Actinomycin D (Dactinomycin); Adriamycin (doxorubicin); CPT-11 (irinotecan); Cabozantinib (XL 184); Camptosar (irinotecan); Dactinomycin (); Doxil (doxorubicin liposome); Etoposide (); Ifosfamide (); Radiotherapy (); Topotecan (); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); doxorubicin liposome (); irinotecan ()
CLINICAL TRIAL 23912
A Modular, Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120, a Dual-targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD-19 in Participants with Multiple Myeloma
Condition: Multiple Myeloma
Intervention: AZD0120 (); CC-5013 (Lenalidomide); Lenalidomide (Revlimid); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)